10-K/A: PepGen Inc. Files Amended 10-K to Correct Internal Controls Language

PepGen Inc. has filed an amendment to its annual report on Form 10-K to include previously omitted internal controls language from its auditor's report.

Summary

• PepGen Inc. filed an amendment to its annual report on Form 10-K for the fiscal year ended December 31, 2023.
• The amendment's sole purpose is to include internal controls language that was inadvertently omitted from KPMG LLP's Report of Independent Registered Public Accounting Firm.
• The revised auditor's report and updated consent from KPMG LLP are included in the amendment.
• All other information in the original Form 10-K remains unchanged.
• The amendment includes new certifications from the company's principal executive officer and principal financial officer as required by the Securities Exchange Act of 1934.
• The company had cash, cash equivalents, and marketable securities of $110.4 million as of December 31, 2023, excluding proceeds from subsequent offerings.
• The company believes its current resources will fund operations for at least the next 12 months.
• The company reported a net loss of $78.6 million for the year ended December 31, 2023, compared to a net loss of $69.1 million in 2022.
• Research and development expenses were $68.1 million in 2023, up from $54.1 million in 2022.
• The company's total assets were $143.1 million as of December 31, 2023, down from $217.4 million in 2022.

Sentiment

Score: 5

Explanation: The document is neutral to slightly negative. While the company has corrected an error and has sufficient funds for the next 12 months, the increased net loss and decreased assets are concerning. The need for future capital raises is also a risk.

Positives

• The company has sufficient cash and marketable securities to fund operations for at least the next 12 months.
• The company has taken steps to correct an error in its original filing by including the missing internal controls language.

Negatives

• The company experienced a net loss of $78.6 million in 2023, which is an increase from the $69.1 million loss in 2022.
• The company's total assets decreased from $217.4 million in 2022 to $143.1 million in 2023.

Risks

• The company has incurred significant operating losses and negative cash flows since inception.
• The company's future success depends on its ability to develop and obtain regulatory approval for its product candidates.
• The company may need to raise additional capital through equity, debt, or strategic partnerships, and there is no guarantee that such funding will be available on acceptable terms.
• Failure to obtain additional funding could lead to delays, reductions, or elimination of product development efforts.

Future Outlook

The company believes its current cash, cash equivalents, and marketable securities, along with proceeds from recent offerings, will be sufficient to fund its planned operations for at least the next 12 months. The company expects to finance future operations through equity sales, debt financings, strategic partnerships, or other capital resources.

Management Comments

• The company's principal executive officer and principal financial officer certified that the report does not contain any untrue statements or omissions of material fact and fairly presents the company's financial condition and results of operations.

Industry Context

PepGen is a clinical-stage biotechnology company focused on developing oligonucleotide therapeutics for severe neuromuscular and neurologic diseases. The company's financial results and operational updates are relevant to investors and stakeholders in the biotechnology and pharmaceutical industries, particularly those interested in companies developing novel therapies for rare diseases.

Comparison to Industry Standards

• PepGen's financial performance is typical of a clinical-stage biotechnology company, with significant research and development expenses and net losses as it progresses its drug development programs.
• Comparable companies in the biotechnology sector, such as Sarepta Therapeutics and BioMarin Pharmaceutical, also experience high R&D costs and net losses during their development phases.
• PepGen's cash burn rate and runway are important metrics for investors to monitor, as they indicate the company's ability to fund its operations until it achieves profitability or secures additional funding.
• The company's reliance on external funding is common in the biotech industry, where companies often need to raise capital through equity or debt offerings to support their research and development activities.

Related Party Transactions

• The company has a technology license agreement with Oxford University Innovation Limited (OUI), which is a related party.
• The company had a services agreement with Carnot Pharma, LLC, which is controlled by RA Capital Management, L.P., a related party.
• The company paid compensation to board members affiliated with OUI and RA Capital Management, L.P.

Stakeholder Impact

• Shareholders may be concerned about the increased net loss and decreased assets.
• Employees may be impacted by the company's financial performance and future funding needs.
• Customers and suppliers may be affected by the company's ability to continue its research and development activities.
• Creditors may be impacted by the company's financial performance and ability to repay debts.

Next Steps

• The company will continue to pursue its business plan to develop and obtain regulatory approval for its product candidates.
• The company will likely need to seek additional financing through equity, debt, or strategic partnerships.
• The company will continue to monitor its cash burn rate and runway to ensure it has sufficient resources to fund its operations.

Key Dates

Keywords

PepGen, 10-K, Amendment, Financial Statements, Internal Controls, Auditor Report, Biotechnology, Oligonucleotide Therapeutics, Neuromuscular Diseases, Net Loss, Research and Development, Cash Flow, KPMG